At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF- 06865571 FOR 2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
In Brief
A Phase 1 clinical trial evaluating Placebo and PF-06865571 for Non-alcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease. Completed, enrolled 48 participants across 6 sites.
Detailed Summary
2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionMar 2019
Study CompletionApr 2019
TodayJul 2026
First PostedMay 1, 2018
Enrollment StartJun 21, 2018
Primary CompletionMar 8, 2019
Study CompletionApr 4, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.2 years ago
Interventions
Placebodrug
tablet, 0 mg, 14 days, every 12 hours
PF-06865571drug
tablet, 50 mg, 14 days, every 12 hours
PF-06865571drug
tablet, 300 mg, 14 days, every 12 hours